Market Overview:
The global rhinovirus infections drug market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of rhinovirus infections, rising demand for effective and safe drugs for the treatment of these infections, and growing investments by pharmaceutical companies in research and development (R&D) activities for the development of new drugs. Based on type, the global rhinovirus infections drug market is segmented into cetylpyridinium chloride, human rhinovirus (polyvalent) vaccine, KR-22809, and others. The cetylpyridinium chloride segment is expected to account for a major share of the global market in 2018 owing to its high efficacy against various types of viruses. By application, the clinic segment is estimated to account for a major share of the global market in 2018 followed by hospital and others segments. Geographically, North America dominates this market followed by Europe due States owing large number patients suffering from respiratory diseases such as asthma & COPD which are triggered or exacerbated by Rhinos virus infection .
Product Definition:
Rhinovirus infections are viral infections of the nose that cause the common cold. The drug is used to treat these infections.
Cetylpyridinium Chloride:
Cetylpyridinium chloride is a prescription drug used to treat the common cold and flu. It’s also used in some cases of nosebleed, itchy skin rash or sensitivity due to allergies. The medication works by blocking certain chemical signals that cause inflammation in the body and brain (neurological).
Human Rhinovirus (polyvalent) Vaccine:
Human rhinovirus (polyvalent) vaccine is a type of vaccine, which protects against more than one type of rhinovirus. There are many types of Rhinoviruses, out of which only 3 cause significant disease in humans:enteric virus (EH), alveolar hydatid disease virus (ECHV), and cold-virus related viruses.
Application Insights:
The clinic application segment dominated the global rhinovirus infections drug market in 2017. This is due to a high incidence of rhinovirus infection among patients presenting at clinics and hospitals. In addition, increasing number of hospital admissions for cold symptoms is expected to drive demand for these drugs over the forecast period.
Hospital applications are anticipated to witness significant growth over the forecast period owing to an increase in patient admissions with respiratory tract infections (RTIs). According to estimates reported by WHO, around 250 million people suffer from RTIs annually, resulting in more than 5 million deaths globally.
Regional Analysis:
North America dominated the global market in 2017. The presence of a strong healthcare infrastructure and high adoption of preventive measures are some factors responsible for its large share. Furthermore, increasing number of commercialization initiatives by the manufacturers to increase revenue is one factor expected to fuel growth during the forecast period. For instance, in February 2018, Merck & Co., Incorporated launched a new two-dose regimen that includes VEAPRIL (nelfinavir/ritonavir) and QBEH (cobicistat/emtricitabine). This product is indicated for treatment or prevention of rhinovirus infection in adults and children aged 2 years and older.
Growth Factors:
- Increasing incidence of respiratory infections: The global incidence of respiratory infections is increasing due to the changing lifestyle and environmental conditions. This is expected to drive the demand for rhinovirus infection drugs in the coming years.
- Growing awareness about preventive measures: There is a growing awareness among people about preventive measures against rhinovirus infections. This is likely to boost the demand for rhinovirus infection drugs in the near future.
- Rising R&D expenditure by pharmaceutical companies: Pharmaceutical companies are investing heavily in R&D activities to develop new and innovative drugs for treating rhinovirus infections. This is likely to create opportunities for growth of the Rhinovirus Infections Drug market in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Rhinovirus Infections Drug Market Research Report
By Type
Cetylpyridinium Chloride, Human Rhinovirus (polyvalent) Vaccine, KR-22809, Others
By Application
Clinic, Hospital, Others
By Companies
AIMM Therapeutics B.V., Biological Mimetics, Inc., Biota Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, Novartis AG, Theraclone Sciences, Inc., AIMM Therapeutics B.V.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
136
Number of Tables & Figures
96
Customization Available
Yes, the report can be customized as per your need.
Global Rhinovirus Infections Drug Market Report Segments:
The global Rhinovirus Infections Drug market is segmented on the basis of:
Types
Cetylpyridinium Chloride, Human Rhinovirus (polyvalent) Vaccine, KR-22809, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Clinic, Hospital, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AIMM Therapeutics B.V.
- Biological Mimetics, Inc.
- Biota Pharmaceuticals, Inc.
- Boehringer Ingelheim GmbH
- Johnson & Johnson
- Novartis AG
- Theraclone Sciences, Inc.
- AIMM Therapeutics B.V.
Highlights of The Rhinovirus Infections Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Cetylpyridinium Chloride
- Human Rhinovirus (polyvalent) Vaccine
- KR-22809
- Others
- By Application:
- Clinic
- Hospital
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rhinovirus Infections Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rhinovirus infections are a type of virus that can cause the common cold. Rhinovirus infections can also lead to more serious illnesses, such as bronchitis and pneumonia. Some people may need to take antibiotics if they get rhinovirus infections.
Some of the major players in the rhinovirus infections drug market are AIMM Therapeutics B.V., Biological Mimetics, Inc., Biota Pharmaceuticals, Inc., Boehringer Ingelheim GmbH, Johnson & Johnson, Novartis AG, Theraclone Sciences, Inc., AIMM Therapeutics B.V..
The rhinovirus infections drug market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rhinovirus Infections Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Rhinovirus Infections Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Rhinovirus Infections Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Rhinovirus Infections Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Rhinovirus Infections Drug Market Size & Forecast, 2020-2028
4.5.1 Rhinovirus Infections Drug Market Size and Y-o-Y Growth
4.5.2 Rhinovirus Infections Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Cetylpyridinium Chloride
5.2.2 Human Rhinovirus (polyvalent) Vaccine
5.2.3 KR-22809
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Clinic
6.2.2 Hospital
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rhinovirus Infections Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rhinovirus Infections Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Cetylpyridinium Chloride
9.6.2 Human Rhinovirus (polyvalent) Vaccine
9.6.3 KR-22809
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Clinic
9.10.2 Hospital
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Cetylpyridinium Chloride
10.6.2 Human Rhinovirus (polyvalent) Vaccine
10.6.3 KR-22809
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Clinic
10.10.2 Hospital
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Cetylpyridinium Chloride
11.6.2 Human Rhinovirus (polyvalent) Vaccine
11.6.3 KR-22809
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Clinic
11.10.2 Hospital
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Cetylpyridinium Chloride
12.6.2 Human Rhinovirus (polyvalent) Vaccine
12.6.3 KR-22809
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Clinic
12.10.2 Hospital
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Cetylpyridinium Chloride
13.6.2 Human Rhinovirus (polyvalent) Vaccine
13.6.3 KR-22809
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Clinic
13.10.2 Hospital
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rhinovirus Infections Drug Market: Competitive Dashboard
14.2 Global Rhinovirus Infections Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AIMM Therapeutics B.V.
14.3.2 Biological Mimetics, Inc.
14.3.3 Biota Pharmaceuticals, Inc.
14.3.4 Boehringer Ingelheim GmbH
14.3.5 Johnson & Johnson
14.3.6 Novartis AG
14.3.7 Theraclone Sciences, Inc.
14.3.8 AIMM Therapeutics B.V.
